Skip to main content

LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021

Written by Customer Service on . Posted in Public Companies.

STOCKHOLM – LIDDS (Nasdaq First North: LIDDS) announced today that the company will apply for a relisting of its shares from Nasdaq First North to Nasdaq Stockholm Main Market in 2021.LIDDS is in a strong growth and expansion phase with several key projects in clinical and preclinical phases, including Phase III Liproca Depot out-licensing, the Phase I NanoZolid-docetaxel study and an extensive preclinical program in immuno-oncology.“A listing on Nasdaq Stockholm Main Market is a natural next step in the company´s development. A move to Nasdaq Stockholm’s main market can contribute to increased interest from a broader investor base while at the same time increase the visibility and exposure of LIDDS, in Sweden and globally”, said Monica Wallter, CEO, LIDDS.“It is clear that our shareholder base has developed significantly in recent years, both in terms of number of shareholders and that we now have larger and longer-term institutional and private investors”, says Jan Törnell, Chairman of the Board of LIDDS.A transition from Nasdaq First North to Nasdaq Stockholm’s Main Market has the potential to increase LIDDS visibility both locally and internationally. For more information, please contact:Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.comLIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months or more. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.